Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 16/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.87 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731306 | 0.93 | KCNJ1 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL5763269 | 0.89 | KCNJ1 (0.84) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL4792525 | 0.87 | KCNJ1 (0.66) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL3156895 | 0.87 | HRH3 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL5653299 | 0.87 | HRH3 (0.93) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL2723230 | 0.86 | KCNJ1 (0.84) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL286800 | 0.86 | KCNJ1 (0.84) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL519334 | 0.85 | KDM4E (0.67) | KCNJ1KCNH2 | |
| SCHEMBL3156570 | 0.85 | HRH3 (0.97) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL914324 | 0.85 | HRH3 (0.97) | KCNJ1KCNH2HRH3SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| EP-1937681-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| WO-2008055013-A2 | 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007033232-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| CN-1902185-A | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | KCNJ1 1530/4885KCNH2 2514/4885HRH3 4052/4885 |
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | KCNJ1 4514/4885KCNH2 3089/4885HRH3 1544/4885 |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | KCNJ1 4037/4885KCNH2 2366/4885HRH3 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.